39th week of 2021 patent applcation highlights part 28 |
Patent application number | Title | Published |
20210300920 | KRAS Mutant Protein Inhibitors - The invention relates to a KRAS mutant protein inhibitors of formula (I), a composition containing the inhibitors and the use thereof. | 2021-09-30 |
20210300921 | EP4 INHIBITORS AND SYNTHESIS THEREOF - The present invention provides N-((4-(2-ethyl-4,6-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)phenethyl)carbamoyl)-4-methylbenzenesulfonamide compositions, and the use thereof for treating a proliferative disorder. | 2021-09-30 |
20210300922 | PYRIDOPYRIMIDINES AS HISTAMINE H4-RECEPTOR INHIBITORS - The invention relates to compounds of formula (I): | 2021-09-30 |
20210300923 | SULFOXIMINE COMPOUND AS BROMODOMAIN PROTEIN INHIBITOR AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF - The present invention relates to a sulfoximine compound represented by formula (I) as a bromodomain protein inhibitor and a pharmaceutically acceptable salt thereof and to a preparation method, pharmaceutical composition, and medical use thereof. | 2021-09-30 |
20210300924 | 5-[6-[[3-(4,5,6,7-TETRAHYDROPYRAZOLO[4,3-C]PYRIDIN-1-YL)AZETIDIN-1-YL]METH- YL]MORPHOLIN-4-YL]QUINOLINE-8-CARBONITRILE DERIVATIVES AND SIMILAR COMPOUNDS AS TLR7-9 ANTAGONISTS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS - The present invention relates to a compound of formula (I) wherein R | 2021-09-30 |
20210300925 | 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS - The present invention relates to substituted pyrrolopyridinones and substituted pyrazolopyridinones which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer. | 2021-09-30 |
20210300926 | NEW BETA-LACTAMASE INHIBITORS TARGETING GRAM NEGATIVE BACTERIA - The present invention relates to a compound of the following formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, notably for use as β-lactamase inhibitors, notably in the treatment of a disease caused by gram negative bacteria, in particular enterobacteria, as well as pharmaceutical compositions containing such a compound and a process to prepare such a compound. | 2021-09-30 |
20210300927 | ISOXAZOLYL-CARBONYLOXY AZABICYCLO[3.2.1]OCTANYL COMPOUNDS AS FXR ACTIVATORS - The disclosure relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): | 2021-09-30 |
20210300928 | METHODS AND COMPOSITIONS FOR SUBSTITUTED ARYLCYCLOHEPTANE ANALOGS - In one aspect, the disclosure relates to methods for preparation of intermediates useful for the preparation of aryl-cycloheptene scaffolds. In a further aspect, the disclosed methods pertain to the preparation of compounds comprising an aryl-cycloheptene structure. The disclosed methods utilize abundant starting materials and simple reaction sequences that can be used to modularly and scalably assemble common such cores. In various aspects, the present disclosure pertains to compounds prepared using the disclosed methods. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure. | 2021-09-30 |
20210300929 | METHOD FOR ISOLATION OF CYTISINE - The invention concerns a method for isolation of cytisine from plant material. The method according to the invention, consists in extraction of the plant raw material by lower alcohol, acidified with mineral acid to pH within a range 1.5-3.5. The combined alcohol-aqueous extracts are concentrated under vacuum distillation till the alcohol is eliminated and after filtration they are extracted with chloroform, methylene chloride, butyl acetate or normal butanol in a ratio of 1:1. The purified from ballast substances acid aqueous concentrate is alkalized to pH 9-12 with alkaline hydroxide or ammonium hydroxide and the resulting alkaline aqueous concentrate is extracted at least twice with chloroform, methylene chloride, butyl acetate or normal butanol in a ratio of concentrate:extractant of 1:5 to 1:10. The combined organic extracts are evaporated to dryness, then acetone or ethyl acetate are added to obtain a suspension which is allowed to crystallize completely at 5-10° C., then it is filtered and dried. The isolated product is with a high purity and yield. | 2021-09-30 |
20210300930 | POLYMORPHS OF SEPIAPTERIN AND SALTS THEREOF - Disclosed are crystalline forms of sepiapterin free base selected from polymorphs A, B, C, D, E, F, and G, and combinations thereof, as well as crystalline polymorphs of salts of sepiapterin. Also disclosed are pharmaceutical compositions containing one or more such polymorphs and methods for preparing such polymorphs. Sepiapterin is useful in the treatment of a number diseases associated with low cellular levels of BH4, for example, phenylketonuria. | 2021-09-30 |
20210300931 | PHARMACEUTICAL SALTS, PHYSICAL FORMS, AND COMPOSITIONS OF PYRROLOPYRIMIDINE KINASE INHIBITORS, AND METHODS OF MAKING SAME - Disclosed methods of making certain pyrrolopyrimidine derivatives, which are useful in the treatment of proliferation disorders and other diseases related to the dysregulation of kinase (such as, but not limited to, EGFR (including HER), Alk, PDGFR, BLK, BMX/ETK, BTK, FLT3(D835Y), ITK, JAK1, JAK2, JAK3, TEC AND TXK) and/or the respective pathways, salts, polymorphs, and amorphous forms of said compounds, synthetic intermediates for preparing said compounds, and pharmaceutical compositions comprising said compounds and methods for making such compositions. | 2021-09-30 |
20210300932 | CYCLIC PEPTIDES TARGETING ALPHA-4-BETA-7 INTEGRIN - There is described herein antagonists of α4β7 integrin, and more particularly to cyclic peptide antagonists. Accordingly, there is described herein a compound of formula (I) wherein R | 2021-09-30 |
20210300933 | IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME - The present disclosure provides a compound of Chemical Formula (1) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same: | 2021-09-30 |
20210300934 | MACROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS - Macrocyclic Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, and Formula VIII or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. | 2021-09-30 |
20210300935 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS - Pyrazolo-quinazoline derivatives of formula (Ia) or (Ib) as defined in the specification, and pharmaceutically acceptable salts thereof, processes for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer. | 2021-09-30 |
20210300936 | PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES AS A2A RECEPTOR ANTAGONIST - Disclosed herein is a pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof useful as A2A receptor antagonist, and a pharmaceutical composition comprising the same. Also disclosed herein is a method of treating cancer using the pyrazolotriazolopyrimidine derivative or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof as A2A receptor antagonist. | 2021-09-30 |
20210300937 | Novel Labelled Cannabinergic Ligands and Related Analogs - Novel cannabinoid ligands represented by the general formulas I, II, and III and methods for preparation and use within which one or more of a fluorescent ligand, nitroxide spin label, metal chelate, biotin moiety, or group with enhanced polarity may be incorporated. The compounds can bind to and modulate the cannabinoid CB1 and CB2 receptors and thereby considered specific ligands for these receptors. Some of the disclosed compounds that bind to cannabinoid CB1 and CB2 receptors can exhibit tight or irreversible binding characteristics for these receptors. Due to the presence of the imaging/diagnostic and/or therapeutic functional groups including fluorescent groups, nitroxide spin labels, metal chelates, biotin moieties, and groups with enhanced polarity, the disclosed compounds may be useful as imaging/diagnostic tools and/or therapeutic agents. | 2021-09-30 |
20210300938 | METHODS FOR CRYSTALLIZATION OF DRUGS - Methods are disclosed including methods for crystallizing a material such as a drug. An example method may include combining a nucleation initiator, a surfactant solution, and an amorphous form of a drug to form a drug precursor dispersion/suspension. The method may also include incubating the drug precursor dispersion/suspension to allow the drug to convert from the amorphous form to a crystalline form. | 2021-09-30 |
20210300939 | Single Molecule Compounds Providing Multi-Target Inhibition of BTK and Other Proteins and Methods of Use Thereof - The invention relates to compounds useful for inhibiting BTK and at least one other protein and to methods of treating diseases including cancer by administration of a compound(s) of Formula I-IV or pharmaceutically acceptable salts thereof as defined herein. | 2021-09-30 |
20210300940 | TLR7/8 ANTAGONISTS AND USES THEREOF - Compounds of Formula (I) and pharmaceutically acceptable compositions thereof are useful as TLR7/8 antagonists. | 2021-09-30 |
20210300941 | BISPECIFIC DEGRADERS - Disclosed are degraders, pharmaceutical compositions containing them, and methods of making and using the degraders to treat diseases and disorders characterized by aberrant protein activity that can be targeted by cereblon. | 2021-09-30 |
20210300942 | FUSED DIHYDRO-4H-PYRAZOLO[5,1-C][1,4]OXAZINYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS - Disclosed are compounds of Formula (I): | 2021-09-30 |
20210300943 | OGA INHIBITOR COMPOUNDS - The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations. | 2021-09-30 |
20210300944 | FUSED TRICYCLIC HETEROCYCLE COMPOUNDS AND THERAPEUTIC USES THEREOF - This application discloses a new class of fused tricyclic heterocycles of formula (I), preparation methods thereof, pharmaceutical compositions comprising these compounds, and pharmaceutically acceptable salts, solvates, or prodrugs thereof, and their uses for the treatment of diseases in which modulation of STING is beneficial, for example, cancers, pre-cancerous disorders, and viral infections. | 2021-09-30 |
20210300945 | Crystalline Forms of Cabotegravir Sodium - The present invention relates to crystalline forms of cabotegravir sodium and to methods for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising one of said crystalline forms of cabotegravir sodium, preferably in a predetermined and/or effective amount, and at last one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment and/or prophylaxis of viral infections such as HIV infections. | 2021-09-30 |
20210300946 | PYRIDINE MACROCYCLE COMPOUNDS AS ASK1 INHIBITING AGENTS - Provided are compounds of Formula (I′), including compounds of Formulas (I), (II), (III), (IIIA) and (IIIB), wherein L, R | 2021-09-30 |
20210300947 | NOVEL HETEROARYL HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE - The present invention relates to compounds of formula (I), ab (I), wherein R1 to R3 and L are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds. | 2021-09-30 |
20210300948 | 1H-PYRROLE-2,5-DIONE COMPOUNDS AND METHODS OF USING THEM TO INDUCE SELF-RENEWAL OF STEM/PROGENITOR SUPPORTING CELLS - The present invention relates to 1H-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells, including inducing the stem/progenitor cells to proliferate while maintaining, in the daughter cells, the capacity to differentiate into tissue cells. | 2021-09-30 |
20210300949 | MULTIFUNCTIONAL IMMUNITY-TARGETED MICROMOLECULE ANTI-CANCER MEDICINE BESTAZOMIB (BESTAZOMIB) AND PREPARATION METHOD AND APPLICATION THEREOF - A multifunctional immunity-targeted micromolecule anti-cancer medicine Citrate Bestazomib and preparation method and application thereof. The structure of the multifunctional immunity-targeted micromolecule anti-cancer medicine Bestazomib Citrate is shown as follows: | 2021-09-30 |
20210300950 | SOLID STATE FORMS OF IXAZOMIB CITRATE - The present disclosure encompasses solid state forms of Ixazomib Citrate and pharmaceutical compositions thereof. Also disclosed are processes for preparation of Ixazomib Citrate. | 2021-09-30 |
20210300951 | COMPOSITION FOR ORGANIC OPTOELECTRONIC DEVICE, ORGANIC OPTOELECTRONIC DEVICE, AND DISPLAY DEVICE - A composition for an organic photoelectronic device, an organic photoelectronic device, and a display device, the composition comprising a first compound represented by Chemical Formula 1, and a second compound represented by Chemical Formula 2: | 2021-09-30 |
20210300952 | SILICON HYDRAZIDO PRECURSOR COMPOUNDS - Provided are certain silicon precursor compounds which are useful in the formation of silicon-containing films in the manufacture of semiconductor devices, and more specifically to compositions and methods for forming such silicon-containing films, such as films comprising silicon, silicon nitride, silicon oxynitride, silicon dioxide, a carbon-doped silicon nitride, or a carbon-doped silicon oxynitride film. | 2021-09-30 |
20210300953 | OPTICALLY-ACTIVE CYCLOPENTENONE DERIVATIVES - The present invention provides: industrially desirable and novel optically-active cyclopentenone derivatives; and a novel industrial manufacturing method. The novel optically-active cyclopentenone derivatives and method for manufacturing the same are, respectively: an intermediate for industrially desirable and novel prostaglandin derivatives and the like; and a method for manufacturing the same. It is expected that the present invention will be commercialized and industrialized. | 2021-09-30 |
20210300954 | IONIC TAGS FOR SYNTHESIS OF OLIGORIBONUCLEOTIDES - The invention relates to the chemical synthesis of oligonucleotides, e.g., oligoribonucleotides. In another aspect, the invention relates to compounds of formula (II): | 2021-09-30 |
20210300955 | MOLYBDENUM COMPOUND AND METHOD OF MANUFACTURING INTEGRATED CIRCUIT DEVICE USING THE SAME - A molybdenum compound and a method of manufacturing an integrated circuit device, the molybdenum compound being represented by the following General Formula (I): | 2021-09-30 |
20210300956 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES - Provided are organoiridium compounds that are useful as emitters in OLEDs. The compounds have Formula I L | 2021-09-30 |
20210300957 | PLATINUM COMPLEXES HAVING FERROCENE LIGANDS FOR THE CATALYSIS OF THE ALKOXYCARBONYLATION OF ETHYLENICALLY UNSATURATED COMPOUNDS - Platinum complexes having ferrocene ligands for the catalysis of the alkoxycarbonylation of ethylenically unsaturated compounds. | 2021-09-30 |
20210300958 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS - Novel aminoglycosides, represented by Formulae Ia and Ib, as defined in the instant specification, designed to exhibit stop codon mutation readthrough activity, are provided. Also provided are pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic diseases and disorders, such as diseases and disorders associated with stop codon mutations. | 2021-09-30 |
20210300959 | NOVEL BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND USE THEREOF AS ANTI-CANCER AGENT COMPRISING THE SAME - According to the present invention, there are provided a benzimidazole carbamate-sugar compound conjugate compound represented by the following Chemical Formula 1, a preparation method thereof, and a use thereof as an anti-cancer agent: | 2021-09-30 |
20210300960 | SUGAR DERIVATIVE OR SALT THEREOF, AND ANTIBACTERIAL AGENT OR ANTIBACTERIAL ACTIVITY ENHANCER USING SAME - A saccharide derivative represented by Chemical Formula (1) or (2), or a salt thereof, includes units of a monosaccharide linked to each other in a chainlike or cyclic manner through glycosidic bonding and has antimicrobial action. In the formulae, R | 2021-09-30 |
20210300961 | METHOD FOR PREPARING 3'-O-AMINO-2'-DEOXYRIBONUCLEOSIDE-5'-TRIPHOSPHATES - Methods for preparing 3′-O-amino-2′-deoxyribonucleoside-5′-triphosphates with reduced 3′-hydroxy-2′-deoxyribonucleoside-5′-triphosphate contamination by converting 3′-(N-acetone-oxime)-2′-deoxynucleoside triphosphate to 3′-O-amine-2′-deoxynucleoside triphosphate by treatment with an aryl-oxyamine and compositions produced therefrom. | 2021-09-30 |
20210300962 | LIPID PRODRUGS OF PREGNANE NEUROSTEROIDS AND USES THEREOF - The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof. | 2021-09-30 |
20210300963 | PREPARATIONS OF HYDROPHOBIC THERAPEUTIC AGENTS, METHODS OF MANUFACTURE AND USE THEREOF - The present invention further provides method of preparing nanocrystals of a hydrophobic therapeutic gent such as fluticasone or triamcinolone, pharmaceutical compositions (e.g., topical or intranasal compositions) thereof and methods for treating and/or preventing the signs and/or symptoms of disorders such as blepharitis, Meibomian gland dysfuntion or skin inflammatiom or a respiratory disease (e.g., asthma). | 2021-09-30 |
20210300964 | PROTEIN FRAGMENTATION CONTROL STRATEGY BY RE-OXIDATION IN DOWNSTREAM CHROMATOGRAPHY - Methods for the production of high purity recombinant protein such as monoclonal antibodies (mAb) using disulfide bond re-oxidation are provided. In particular, the present disclosure provides methods for converting partial molecules (e.g., antibody fragments) to full molecules (e.g., full antibodies) comprising admixing a starting solution comprising the partial molecules with a redox buffer comprising a redox pair which comprises at least one thiol reducing agent (e.g., cysteine) and at least one thiol oxidizing agent (e.g., cystine), wherein the redox buffer re-oxidizes the partial molecules to full molecules. The disclosed methods can be used, e.g., to prevent or mitigate the formation of partial molecules during protein purification, or to reprocess or rescue a solution comprising partial molecules (e.g., a partially degraded pharmaceutical formulation). | 2021-09-30 |
20210300965 | DEVICES AND METHODS FOR THE SENSITIVE DETECTION AND QUANTITATION OF BIOMOLECULES - The present disclosure provides devices, systems, kits and methods useful for quantitation of biomolecules such as intact proteins and nucleic acids. | 2021-09-30 |
20210300966 | SOLUTION PHASE SYNTHESIS OF BETA-TURN PEPTIDOMIMETIC CYCLIC SALTS - The present disclosure relates to methods of preparing and crystallizing β-turn cyclic peptidomimetic salts of formula I: | 2021-09-30 |
20210300967 | NOVEL PEPTIDES AND ITS DERIVATIVES CAPABLE OF STIMULATING CYTOKINE RELEASE - The present invention relates to a novel peptide that can stimulate the release of cytokines, as well as to the use of the peptide as a medicament. | 2021-09-30 |
20210300968 | UTERINE CANCER TREATMENTS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2021-09-30 |
20210300969 | IL-17A BINDING PEPTIDES AND MEDICAL USES THEREOF - The invention relates to IL-17A binding peptides, inhibitors of the interaction of IL-17A with the receptor IL-17RA, and to bioconjugates, dimers, pharmaceutical compositions and medical use thereof. | 2021-09-30 |
20210300970 | COVID-19 VACCINE - Provided herein are antigenic peptides comprising the SARS-CoV-2 spike protein receptor binding domain (CRBD) polypeptide or portions thereof, linked to a non-catalytic, non-toxic tetanus toxin variant (i.e., a modified tetanus toxin or “MTT”) and vaccine compositions comprising the same. In addition, provided herein are methods for making and using CRBD-MTT fusion proteins as immunogenic agents. | 2021-09-30 |
20210300971 | STABILIZED RSV F PROTEINS AND USES THEREOF - The disclosure relates to stable RSV F proteins and immunogenic compositions containing the same, as well as methods of using the immunogenic compositions and compositions comprising the RSV F proteins. | 2021-09-30 |
20210300972 | COMPOUND HAVING AFFINITY SUBSTANCE TO ANTIBODY, CLEAVABLE PORTION, AND REACTIVE GROUP, OR SALT THEREOF - Compounds having an affinity substance to an antibody, a cleavable portion, and a reactive group, or a salt thereof, are represented by the following Formula (I): | 2021-09-30 |
20210300973 | LACTOBACILLUS ACIDOPHILUS SURFACE LAYER PROTEIN A (SLPA) AS A THERAPEUTIC AGENT FOR THE TREATMENT OF INFLAMMATORY DISEASES - The current invention provides a recombinant bacterium, the recombinant bacterium being genetically modified to decrease or eliminate the display of lipoteichoic acid (LTA), surface layer protein B (SlpB) and surface layer protein X (SlpX) on the surface of said bacterium. Efficacious therapies for a subject suffering from an inflammation mediated disease are also provided. The methods of the current invention comprise administering to a subject in need thereof a therapeutically effective amount of the recombinant | 2021-09-30 |
20210300974 | ARTIFICIAL TRANSCRIPTION FACTORS COMPRISING A SLIDING DOMAIN AND USES THEREOF - The present invention relates to compositions which may comprise a non-naturally occurring or engineered artificial transcription factor, wherein the transcription factor may comprise a sequence specific DNA binding domain, a sliding domain, and one or more linkers, wherein the DNA binding domain and the sliding domain are operably connected by the one or more linkers, and uses thereof. Methods involving the use of a non-naturally occurring or engineered artificial transcription factors and pharmaceutical compositions, methods for treating cancer, a degenerative disease, a genetic disease or an infectious disease as well as diagnostic methods are also contemplated by the present invention. | 2021-09-30 |
20210300975 | PROCESS FOR THE SEPARATION AND PURIFICATION OF PHYCOBILIPROTEINS - The present invention relates to a membrane chromatography process for selectively separating and purifying phycobiliproteins starting from aqueous biomasses of cyanobacteria and algae that, in a short time and at reduced cost, allows to obtain phycobiliproteins with a high degree of purity for use in pharmaceutical, cosmetic, or food compositions or as reagents for research. | 2021-09-30 |
20210300976 | Fascin-2 (FSCN2) Variants And Uses Thereof - The present disclosure provides methods of treating subjects having hearing loss, methods of identifying subjects having an increased risk of developing hearing loss, and methods of detecting human Fascin-2 (FSCN2) variant nucleic acid molecules and variant polypeptides. | 2021-09-30 |
20210300977 | CELL-PENETRATING PEPTIDE DIMERS, METHOD FOR PREPARING THE SAME, AND CARGO DELIVERY SYSTEM USING THE SAME - The present invention relates to a cell-penetrating peptide dimer comprising: a first peptide domain consisting of the amino acid sequence of SEQ ID NO: 1; a second 30Kc19a peptide domain consisting of the amino acid sequence of SEQ ID NO: 1; and a peptide linker connecting the first and second peptide domains, a method for preparing the peptide dimer, a cargo delivery system in which a cargo is conjugated to the dimer; and a use thereof. The cell-penetrating peptide dimer according to the present invention may have excellent cell-penetrating properties, thereby being usefully employed as the cargo delivery system. | 2021-09-30 |
20210300978 | DELIVERY OF NRF2 AS THERAPY FOR PROTECTION AGAINST REACTIVE OXYGEN SPECIES - The present invention provides methods and compositions for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, ocular neovascularization, or inflammation, including ocular inflammation. In some embodiments, the methods comprise administering an expression vector that delivers a secretable and cell penetrating Nrf2 to a subject in need thereof. | 2021-09-30 |
20210300979 | NOVEL ANTIMICROBIAL PROTEINS - The present invention relates to a polypeptide comprising a Gram negative endolysin and a peptide selected from the group consisting of an antimicrobial peptide, an amphipathic peptide, a cationic peptide, a sushi peptide or a defensin, wherein the endolysin in turn is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9 and sequences having at least 80% sequence identity with SEQ ID NO:1, SEQ ID NO:2, SEQ ID NOG, SEQ ID NO:4, SEQ ID NOG, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8 and/or SEQ ID NO:9. The present invention relates also to corresponding nucleic acids, vectors, bacteriophages, host cells, compositions and kits. The present inventions also relates to the use of said polypeptides, nucleic acids, vectors, bacteriophages, host cells, compositions and kits in methods for treatment of the human or animal body by surgery or therapy or in diagnostic methods practiced on the human or animal body. The polypeptides, nucleic acids, vectors, bacteriophages, host cells, compositions and kits according to the invention may also be used as an antimicrobial in, e.g., food or feed, in cosmetics, or as disinfecting agent. | 2021-09-30 |
20210300980 | OSTEOGENIC BIOMATERIAL - A composition for enhancing bone tissue repair or regeneration is described. The composition includes osteoactivin or an active peptide fragment thereof and a biocompatible material. Osteogenic orthopedic devices including the osteoactivin-containing composition are also described. The devices and compositions can be used in methods for enhancing bone tissue repair or regeneration by contacting a site in need of bone repair or regeneration in a subject with the osteoactivin-containing composition. | 2021-09-30 |
20210300981 | COMPOSITIONS AND METHODS FOR COMBATING MULTIDRUG-RESISTANT BACTERIA - Provided are peptides, modified peptides, fragments thereof, conjugates thereof, and polymers thereof that have antibacterial activity against bacterial that include but are not limited to multidrug-resistant bacteria. In some embodiments, the presently disclosed subject matter relates to peptides that include the amino acid sequences RTVRCTCI (SEQ ID NO: 2), LSRTVRCTCISI (SEQ ID NO: 3) or VPLSRTVRCTCISI (SEQ ID NO: 4), PESK AIKNLLK AV SKERSKRSP (SEQ ID NO: 11), or KNLLK AV SKERSKRSP (SEQ ID NO: 12), modified peptides thereof, fragments thereof, and conjugates thereof, and any combination thereof. The peptides, modified peptides, fragments thereof, and conjugates thereof can be polymer-functionalized, encapsulated in a particle, embedded in and/or on a solid support, optionally wherein the peptide is formulated for release from the solid support, impregnated in a dressing, optionally wherein the peptide is formulated for release from the dressing, and/or is formulated for use in a nebulizer, for topical administration, and/or for systemic administration. Also provided are medical devices having a support layer with an antibacterial agent embedded therein or associated therewith, methods for inhibiting the growth of and/or killing bacteria, for recruiting immune cells to site of infection, for treating or preventing community and/or nosocomial infections, for inducing a subjects immune system against a pathogen, for treating bacterial infections present in wounds, for treating pulmonary infections, for treating or preventing systemic bacterial infections, and for combination therapies with conventional antibiotics. | 2021-09-30 |
20210300982 | MODIFIED GLUCAGON MOLECULES - The invention generally relates to modified glucagon molecules. In certain embodiments, the invention provides a glucagon molecule that includes one or more modified amino acids to result in the glucagon molecule being soluble at a substantially neutral pH and resistant to fibrillation. Modifications may include, for example, phosphorylation or sulfation. | 2021-09-30 |
20210300983 | ULTRA-LONG ACTING INSULIN-FC FUSION PROTEINS AND METHODS OF USE - The present disclosure provides recombinantly manufactured ultra-long acting insulin-Fc fusion proteins for use in treating canine diabetes. The insulin-Fc fusion proteins comprise an insulin polypeptide linked via a peptide linker to an Fc-fragment of canine origin. Based on the results obtained, creating a treatment that is amenable to low cost manufacturing, exhibits sufficient in vivo bioactivity, displays extended duration of bioactivity, does not induce anti-drug antibodies, and substantially retains is potency over multiple administrations, requires a non-obvious combination of insulin polypeptide, peptide linkers, and species-specific Fc fragment, in addition to selective mutations on one or more of these components. Exemplary ultra-long acting insulin-Fc fusion proteins, polynucleotides encoding these insulin-Fc fusion proteins, and pharmaceutical formulations of exemplary insulin-Fc fusion proteins are provided, in addition to methods of use and preparation. | 2021-09-30 |
20210300984 | LONG-ACTING INSULIN ANALOGUES AND DERIVATIVES THEREOF - The present invention relates to long-acting insulin analogues having an increased in vivo half-life in which the amino acid at position 22 of the B-chain of native insulin is substituted and one or more amino acids of the A-chain or B-chain of native insulin are additionally substituted, and to long-acting insulin analogue derivatives having a further increased in vivo half-life in which an albumin-binding domain is additionally fused to the long-acting insulin analogues. The insulin analogues or insulin analogue derivatives according to the present invention have a significantly increased in vivo half-life, and thus can provide convenience to diabetic patients who self-administer insulin by injection. | 2021-09-30 |
20210300985 | REGULATORY T CELL EPITOPES - The present is directed to compositions comprising regulatory T cell epitopes, wherein said epitopes comprise a polypeptide comprising at least a portion of SEQ NOS: 1-14 and 74-116, fragments and/or variants thereof, as well as methods of producing and using the same. | 2021-09-30 |
20210300986 | T-CELLS COMPRISING TWO DIFFERENT CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF - The present invention provides T-cells modified to express at least two chimeric antigen receptors, wherein one of the CARs binds specifically to an antigen selected from CD138, HER2 and CD24 and another CAR binds specifically a different antigen selected from CD138, HER2 and CD24. Further, the invention provides pharmaceutical compositions comprising these CAR T-cells and their use in treatment of cancer, in particular, ovarian cancer, DNA constructs encoding said CARs and methods for preparation of T-cells expressing said CARs. | 2021-09-30 |
20210300987 | HA-1 SPECIFIC T CELL RECEPTORS AND THEIR USE - The present invention covers an isolated T cell receptor (TCR) specific for one allelic variant of minor histocompatibility antigen 1 (HA-1), in particular the allelic variant HA-1 | 2021-09-30 |
20210300988 | ANTI-KRAS-G12D T CELL RECEPTORS - Disclosed is an isolated or purified T cell receptor (TCR) having antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented in the context of an HLA-Cw*0802 molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal. | 2021-09-30 |
20210300989 | CO-RECEPTOR AFFINITY ENHANCED MAJOR HISTOCOMPATIBILITY CLASS II MOLECULES - The present disclosure provides variant major histocompatibility complex class II (MHCII) beta chains, as well as heterodimers and multimers including MHCII alpha chains and the variant MHCII beta chains. Also provided by the present disclosure are nucleic acids, expression cassettes, and expression vectors encoding the MHCII beta chains. The heterodimers and multimers of the present disclosure have a higher affinity for CD4 co-receptors than comparable reagents including wild type MHCII beta chains, and therefore are advantageous for use in methods of phenotyping or activating CD4 | 2021-09-30 |
20210300990 | METHOD FOR THE PRODUCTION OF BI-FUNCTIONAL CELLS TO TREAT NEOPLASIA - Method for the production of bi-functional cells comprising engineering a starting cell population with a phenotype attributable to human pericytes extracted from adipose tissue (AD-PC), obtaining engineered cells, known as bi-functional AD-PCs, expressing (which means that they produce) simultaneously both the anti-tumor molecule TRAIL and also the truncated form of a chimeric receptor targeted against the GD2 antigen (GD2 tCAR); this dual targeting (understood as reaching a specific target), based on affinity and mediated by both TRAIL and also GD2 tCAR, supports the prediction of combining site-specificity with a prolonged retention of AD-PCs in tumors expressing the antigen GD2, so as to achieve a more effective release of TRAIL for still incurable tumors. | 2021-09-30 |
20210300991 | ENDOGLIN POLYPEPTIDES AND USES THEREOF - In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a truncated, ligand-binding portion of the extracellular domain of endoglin (ENG) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. | 2021-09-30 |
20210300992 | Soluble Polypeptides and Methods of Using Same for Inhibiting Leukemia Inhibitory Factor Activity - Provided are soluble leukemia inhibitory factor receptor (LIFR) polypeptides, soluble glycoprotein 130 (gp130) polypeptides, and soluble fusion proteins and dimers including such polypeptides. The soluble polypeptides bind to leukemia inhibitory factor (LIF). In certain aspects, the soluble polypeptides exhibit increased binding affinity for LIF relative to the corresponding wild-type polypeptides. Also provided are nucleic acids encoding such soluble polypeptides, expression vectors including such nucleic acids, and cells including such nucleic acids and/or expression vectors. Methods of using the soluble polypeptides, including methods of inhibiting LIF activity in an individual in need thereof (e.g., to treat cancer), are also provided. | 2021-09-30 |
20210300993 | QTY FC FUSION WATER SOLUBLE RECEPTOR PROTEINS - The present invention is directed to QTY Fc receptor fusion proteins, methods for the preparation thereof and methods of use thereof. | 2021-09-30 |
20210300994 | BIOFABRICATED LEATHER ARTICLES, AND METHODS THEREOF - The invention herein provides biofabricated leather materials, solutions comprising collagen that can be used to create biofabricated leather materials, articles comprising biofabricated leather materials, methods for making biofabricated materials, methods for applying biofabricated proteins to substrates and methods for making three dimensional biofabricated materials. | 2021-09-30 |
20210300995 | Long-acting fibronectin type III domain fusion protein - The present application belongs to the field of biotechnology and pharmacy, and provides a fusion protein containing a fibronectin type III domain and preparation and application thereof. The structure of the fusion protein comprises a fibronectin type III domain and an insertion sequence, which can maintain the spatial conformation of an inserted protein or an active peptide, and can effectively protect the N-terminal and/or the C-terminal of a target protein, so that the target protein is not easily affected by enzymolysis, and thus obtaining a longer half-life in vivo. | 2021-09-30 |
20210300996 | METHOD FOR PRODUCTION OF ANTIBODY - The present invention provides a method of producing a recombinant antibody efficiently and at low cost. Disclosed is a method of producing an antibody or a fragment thereof, comprising allowing a cell to produce the antibody or the fragment, wherein the cell contains a larger number of copies of an exogenous DNA encoding the light chain or a fragment thereof of the antibody than the number of copies contained in the cell of an exogenous DNA encoding the heavy chain or a fragment thereof of the antibody. The present invention also provides a recombinant vector comprising one copy of a DNA encoding the heavy chain or a fragment thereof of an antibody and two or more copies of a DNA encoding the light chain or a fragment thereof of the antibody; and a transformant. | 2021-09-30 |
20210300997 | IgG STIMULATED REMYELINATION OF PERIPHERAL NERVES - The present invention is based on the discovery of polyclonal IgG's ability to promote Schwann cell maturation, differentiation, and myelin production. Methods for treating non-idiopathic, demyelinating peripheral neuropathies in mammals, where the neuropathy is not immune-mediated or infection-mediated, through the administration of polyclonal IgG are provided. Types of demyelinating peripheral neuropathies treatable with the present invention include peripheral nerve trauma and toxin-induced peripheral neuropathies. Alternatively, a composition of polyclonal IgGs can be applied directly to a peripheral nerve cell to induce maturation, differentiation into a myelinating state, and myelin expression or promote cell survival. | 2021-09-30 |
20210300998 | HUMAN iPSC-DERIVED BRAIN ORGANOIDS AND USES THEREOF - Disclosed are methods of producing human iPSC-derived brain organoids and uses thereof to detect and develop treatment for HCMV-induced brain deformation in developing fetus. | 2021-09-30 |
20210300999 | HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) - The present disclosure is directed to antibodies binding to and neutralizing the coronavirus designated SARS-CoV-2 and methods for use thereof. | 2021-09-30 |
20210301000 | NS1-Binding Protein and Uses Thereof - Provided is an isolated binding protein including an antigen binding domain binding to an NS1 protein. The binding protein can identify and bind to the NS1 protein so as to detect dengue virus. | 2021-09-30 |
20210301001 | ANTIBODY THAT BINDS MURINE WISE PROTEIN - The present invention relates to methods and compositions for the prevention and treatment of renal damage. The invention provides protein-based renal therapeutic agents for administration to subjects in order to prevent or treat renal degeneration or damage. | 2021-09-30 |
20210301002 | ANTI-HSPA5 ANTIBODIES AND USES THEREOF - This disclosure provides anti-HSPA5 antibodies. Also featured is a method for delivering an agent into the brain, spinal cord, or other component of the central nervous system. In addition, methods of identifying a human subject at risk of relapse of neuromyelitis optica (NMO) or neuropsychiatric systemic lupus erythematosus (NP-SLE) are disclosed, as are methods of determining the severity of an attack of NMO or NP-SLE, and methods of diagnosing NP-SLE. | 2021-09-30 |
20210301003 | COMBINATION THERAPY - A method of treating a cognitive or neurodegenerative disease, comprising administering to a patient in need of such treatment an effective amount of an anti-N3pGlu Abeta antibody, an anti-Abeta antibody, or an antibody fragment that binds Amyloid beta and is covalently attached to a polyethylene glycol molecule, in combination with an effective amount of an anti-Tau antibody. | 2021-09-30 |
20210301004 | A PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OR PREVENTION OF A C5-RELATED DISEASE AND A METHOD FOR TREATING OR PREVENTING A C5-RELATED DISEASE - The present invention relates to pharmaceutical compositions for use in the treatment or prevention of a C5-related disease and methods for treating or preventing a C5-related disease. The present invention further relates to dosages and administrations of anti-C5 antibody or pharmaceutical compositions containing the anti-C5 antibody. | 2021-09-30 |
20210301005 | ISOFORM-SELECTIVE ANTI-TGF-BETA ANTIBODIES AND METHODS OF USE - The invention provides isoform-selective anti-TGFβ antibodies and methods of using the same. In particular, isoform-selective anti-TGFβ2, anti-TGFβ3, and anti-TGFβ2/3 monoclonal antibodies are provided, e.g., for the treatment of fibrosis and other TGFβ-related disorders. | 2021-09-30 |
20210301006 | METHODS OF TREATING ACUTE RESPIRATORY DISTRESS SYNDROME - The invention relates to methods and agents useful for treating acute respiratory distress syndrome (ARDS). Methods and agents for treating various physiological and pathological features associated with ARDS are also provided. | 2021-09-30 |
20210301007 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES INVOLVING CXCL1 FUNCTION - The present disclosure relates to antibodies, for example monoclonal antibodies, and their use in clinical patient evaluation and therapy. The present disclosure further relates to a method for modulating the activity of human CXCL-1 protein (hereinafter, referred to as CXCL1). In an aspect, antibodies described herein are capable of being used as a medicament for the prevention and/or treatment of diseases involving CXCL1 function, for example, pathological angiogenesis and inflammatory diseases. | 2021-09-30 |
20210301008 | THERAPIES FOR TREATING ORAL MUCOSITIS WITH POLYCLONAL ANTI-TNFALPHA ANTIBODIES - The present invention is directed to an antibody composition for use in treating oral mucositis, wherein the antibody composition comprises intact blood-derived ovine polyclonal antibodies or intact blood-derived equine polyclonal antibodies that bind to a human tumour necrosis factor α (TNFα). The invention also relates to associated uses, methods, and liquid compositions using/comprising the same. | 2021-09-30 |
20210301009 | INHIBITING GRANULOCYTE MACROPHAGE-COLONY STIMULATING FACTOR (GM-CSF) PREVENTS PRETERM BIRTH - A method of treating a pregnant female subject includes administering to the pregnant female subject an effective amount of a Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) inhibitor, wherein the effective amount of the GM-CSF inhibitor is effective to reduce, prevent or delay preterm birth. | 2021-09-30 |
20210301010 | METHODS FOR TREATING ATOPIC DERMATITIS AND RELATED DISORDERS - The present invention relates to methods for treating atopic dermatitis and related disorders in a subject using an interleukin-13 (IL-13) binding protein, such as an anti-IL-13 antibody or an IL-13-binding fragment thereof. | 2021-09-30 |
20210301011 | COMPOSITION FOR PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES - For example, therapeutic methods and the like for novel IL-8-related diseases using an IL-8 signal inhibitor are provided. Alternatively, for example, therapeutic methods and the like for known or novel IL-8-related diseases using a novel anti-IL-8 antibody are provided. | 2021-09-30 |
20210301012 | Proteins and Uses - The invention is in the field of protein:protein interactions, in particular the stabilisation of protein:protein interactions. Binding proteins are provided for stabilising the interactions, together with compositions comprising the binding proteins. Methods using the binding proteins are also provided, including targeting of cells and also medical uses. | 2021-09-30 |
20210301013 | Methods and Compositions for Treating Aging-Associated Impairments with Trefoil Factor Family Member 2 Modulators - Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include agents modulating the biological concentrations of trefoil factor family member 2 (TFF2) with efficacy in treating and/or preventing aging-related conditions such as neurocognitive disorders. | 2021-09-30 |
20210301014 | MULTI-SPECIFIC ANTIBODIES WITH AFFINITY FOR HUMAN A33 ANTIGEN AND DOTA METAL COMPLEX AND USES THEREOF - Described herein are multi-specific binding agents that bind A33 and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid. Also provided herein are methods of using multi-specific binding agents or compositions thereof for the detection, prevention, and/or therapeutic treatment of diseases characterized by expression of the A33 glycoprotein antigen, in particular, colorectal cancer. | 2021-09-30 |
20210301015 | PRO-ANTIBODY THAT REDUCES OFF-TARGET TOXICITY - The present invention includes proteins, nucleic acids and methods of making and using an activatable antibody (aAb) comprising, in order, the following structure: a first light chain comprising: a first variable light region; a cleavable linker; a first heavy chain comprising: a first variable heavy region; wherein the cleavable linker prevents or reduces the first light chain and the first heavy chain from forming a first antigen binding site against a first antigen; and wherein cleavage of the cleavable linker releases the first heavy chain to allow formation of the first antigen binding site to bind a first antigen. | 2021-09-30 |
20210301016 | DLL3-TARGETING MULTISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF - The disclosure provides multispecific antigen-binding molecules that comprise a first antigen-binding moiety and a second antigen-binding moiety, each of which is capable of binding to CD3 and CD137, but does not bind to CD3 and CD137 at the same time; and a third antigen-binding moiety that is capable of binding to DLL3, preferably human DLL3, which induce T-cell dependent cytotoxity more efficiently whilst circumventing adverse toxicity concerns or side effects that other multispecific antigen-binding molecules may have. The present invention provides multispecific antigen-binding molecules and pharmaceutical compositions that can treat various cancers, especially those associated with DLL3, by comprising the antigen-binding molecule as an active ingredient. | 2021-09-30 |
20210301017 | PROLONGED ADMINISTRATION OF A BISPECIFIC ANTIBODY CONSTRUCT BINDING TO CD33 AND CD3 - The present invention provides a bispecific antibody construct comprising a first binding domain specifically binding to a target such as CD33 and a second binding domain specifically binding to an effector such as CD3 for use in a method for the treatment of myeloid leukemia, wherein the construct is administered in one or more treatment cycles of more than 14 days applying a step dosing comprising at least two steps, a treatment cycle optionally followed by a period without administration of the construct. Moreover, the invention provides a method for the treatment of myeloid leukemia comprising the administration of a therapeutically efficient amount of such bispecific antibody construct and the use of such bispecific antibody construct for the preparation of a pharmaceutical composition for the treatment of myeloid leukemia. | 2021-09-30 |
20210301018 | BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF - The present invention provides bispecific antigen binding proteins (BSAPs) that specifically bind to CD3 and a tumor antigen (e.g., CD19). The present invention also provides uses of the BSAPs for the preparation of pharmaceutical compositions, methods of treating cancer, and kits comprising the BSAPs. | 2021-09-30 |
20210301019 | BI-SPECIFIC FUSION PROTEINS FOR DEPLETION OF REGULATORY T CELLS - The present invention includes fusion proteins, nucleic acids and methods of making and using a protein that binds to antigen presenting cells, such as macrophages and dendritic cells, and an antibody of binding fragment thereof that specifically binds to a regulatory T cell (Treg), wherein the fusion protein reduces the activity of the Treg. | 2021-09-30 |